HIV And HCV adherence and treatment outcomes among people who inject drugs receiving opioid agonist therapy

References

• Akiyama, M. J., Agyemang, L., Arnsten, J. H., Heo, M., Norton, B. L., Schackman, B. R., Linas, B. P., & Litwin, A. H. (2018). Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infectious Diseases, 18(1), 74. https://doi.org/10.1186/s12879-018-2964-5
   PubMedGoogle Scholar
• Akiyama, M. J., Norton, B. L., Arnsten, J. H., Agyemang, L., Heo, M., & Litwin, A. H. (2019). Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: A randomized controlled trial. Annals of Internal Medicine, 170(9), 594–603. https://doi.org/10.7326/M18-1715
   PubMed Web of Science ®Google Scholar
• Axley, P., Ahmed, Z., Ravi, S., & Singal, A. K. (2018). Hepatitis C virus and hepatocellular carcinoma: A narrative review. Journal of Clinical and Translational Hepatology, 6(1), 1–6. https://doi.org/10.14218/JCTH.2017.00067
   PubMed Web of Science ®Google Scholar
• Backus, L. I., Boothroyd, D. B., Phillips, B. R., Belperio, P., Halloran, J., & Mole, L. A. (2011). A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clinical Gastroenterology and Hepatology, 9(6), 509–516.e1. https://doi.org/10.1016/j.cgh.2011.03.004
   PubMed Web of Science ®Google Scholar
• Graham, C. S., Baden, L. R., Yu, E., Mrus, J. M., Carnie, J., Heeren, T., & Koziel, M. J. (2001). Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clinical Infectious Diseases, 33(4), 562–569. https://doi.org/10.1086/321909
   PubMed Web of Science ®Google Scholar
• Grebely, J., Oser, M., Taylor, L. E., & Dore, G. J. (2013). Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. The Journal of Infectious Diseases, 207(Suppl 1), S19–S25. https://doi.org/10.1093/infdis/jis928
   PubMed Web of Science ®Google Scholar
• Information Mediary Corp—Medication Adherence Data Company. (n.d.). Information Mediary Corp. Retrieved August 23, 2021, from https://www.informationmediary.com/
   Google Scholar
• Kattakuzhy, S., Mathur, P., Gross, C., Silk, R., Hill, K., Nussdorf, L., Chaudhury, C., Sternberg, D., Masur, H., Kottilil, S., & Rosenthal, E. (2018). High SVR in PWID with HCV despite imperfect medication adherence: Data from the anchor study. 68, 1–183. https://doi.org/10.1002/hep.30256
   Google Scholar
• McGowan, C. E., & Fried, M. W. (2012). Barriers to hepatitis C treatment. Liver International, 32(Suppl 1), 151–156. https://doi.org/10.1111/j.1478-3231.2011.02706.x
   PubMedGoogle Scholar
• Murdock, R. M., Brizzi, M. B., Perez, O., & Badowski, M. E. (2019). Public health considerations among people who inject drugs with HIV/HCV co-infection: A review. Infectious Diseases and Therapy, 8(1), 23–32. https://doi.org/10.1007/s40121-018-0228-8
   PubMed Web of Science ®Google Scholar
• Myles, A., Mugford, G. J., Zhao, J., Krahn, M., & Wang, P. P. (2011). Physicians’ attitudes and practice toward treating injection drug users infected with hepatitis C virus: Results from a national specialist survey in Canada. Canadian Journal of Gastroenterology, 25(3), 135–139. https://doi.org/10.1155/2011/810108
   PubMed Web of Science ®Google Scholar
• Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., Marks, K., Luetkemeyer, A., Baden, R. P., Sax, P. E., Gane, E., Santana-Bagur, J., Stamm, L. M., Yang, J. C., German, P., Dvory-Sobol, H., Ni, L., Pang, P. S., McHutchison, J. G. … . ION-4 Investigators. (2015). Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine, 373(8), 705–713. https://doi.org/10.1056/NEJMoa1501315
   PubMed Web of Science ®Google Scholar
• Oramasionwu, C. U., Moore, H. N., & Toliver, J. C. (2014). Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: A review. AIDS Patient Care and STDs, 28(5), 228–239. https://doi.org/10.1089/apc.2014.0033
   PubMed Web of Science ®Google Scholar
• Pearlman, B. L., & Traub, N. (2011). Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clinical Infectious Diseases, 52(7), 889–900. https://doi.org/10.1093/cid/cir076
   PubMed Web of Science ®Google Scholar
• Re, L., Kallan, V., Tate, M. J., Localio, J. P., Lim, A. R., Goetz, J. K., Klein, M. B., Rimland, M. B., Rodriguez-Barradas, D., Butt, M. C., Gibert, A. A., Brown, C. L., Park, S. T., Dubrow, L., Reddy, R., Kostman, K. R., Strom, J. R., & Justice, B. L., & Justice, A. C. (2014). Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Annals of Internal Medicine, 160(6), 369-379–379. https://doi.org/10.7326/M13-1829
   Web of Science ®Google Scholar
• Recommendations for Testing, Managing, and Treating Hepatitis C/HCV Guidance. (n.d.). Retrieved August 23, 2021, from https://www.hcvguidelines.org/
   Google Scholar
• Sulkowski, M. S., Mehta, S. H., Torbenson, M. S., Higgins, Y., Brinkley, S. C., de Oca, R. M., Moore, R. D., Afdhal, N. H., & Thomas, D. L. (2007). Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. Aids (London, England), 21(16), 2209–2216. https://doi.org/10.1097/QAD.0b013e3282f10de9
   PubMed Web of Science ®Google Scholar
• Thein, H.-H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008). Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. Aids (London, England), 22(15), 1979–1991. https://doi.org/10.1097/QAD.0b013e32830e6d51
   PubMed Web of Science ®Google Scholar
• Townsend, K., Petersen, T., Gordon, L. A., Kohli, A., Nelson, A., Seamon, C., Gross, C., Tang, L., Osinusi, A., Polis, M. A., Masur, H., & Kottilil, S. (2016). Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. Aids (London, England), 30(2), 261–266. https://doi.org/10.1097/QAD.0000000000000903
   PubMed Web of Science ®Google Scholar
• Trinchet, J.-C., Ganne-Carrié, N., Nahon, P., N’kontchou, G., & Beaugrand, M. (2007). Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World Journal of Gastroenterology, 13(17), 2455–2460. https://doi.org/10.3748/wjg.v13.i17.2455
   PubMed Web of Science ®Google Scholar
• Wyles, D. L., Ruane, P. J., Sulkowski, M. S., Dieterich, D., Luetkemeyer, A., Morgan, T. R., Sherman, K. E., Dretler, R., Fishbein, D., Gathe, J. C., Henn, S., Hinestrosa, F., Huynh, C., McDonald, C., Mills, A., Overton, E. T., Ramgopal, M., Rashbaum, B., Ray, G. … ALLY-2 Investigators. (2015). Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine, 373(8), 714–725. https://doi.org/10.1056/NEJMoa1503153
   PubMed Web of Science ®Google Scholar